E-cigarette, or Vaping, Product Use-Associated Lung Injury: Looking Back, Moving Forward.
Monday, December 21, 2020
Posted by: Natalia Gromov
Brian
A King, PhD, MPH, Christopher M Jones, PharmD, DrPH, MPH, Grant T Baldwin, PhD,
MPH, Peter A Briss, MD, MPH
E-cigarette, or Vaping,
Product Use-Associated Lung Injury: Looking Back, Moving Forward.
Nicotine & Tobacco Research, Volume 22, Issue Supplement_1, December 2020,
Pages S96–S99, https://doi.org/10.1093/ntr/ntaa186
In August 2019, the Centers for Disease Control and Prevention (CDC), U.S. Food
and Drug Administration, state and local health departments, and other clinical
and public health partners began investigating a multistate outbreak of severe
lung injuries that were first identified in July 2019 in Wisconsin and Illinois
among persons with a reported history of e-cigarette, or vaping, product use.
An ensuing investigation focused on understanding the extent, characteristics,
and causes of this novel clinical syndrome, which was subsequently termed
e-cigarette, or vaping, product use-associated lung injury (EVALI). As of
February 18, 2020, a total of 2,807 hospitalized EVALI cases were reported to
CDC from all 50 states, D.C., and two U.S. territories; 68 deaths were
confirmed in 29 states and D.C. National emergency department data and active
case reporting from state health departments documented a sharp increase in
EVALI cases in August 2019, with case counts peaking in September 2019 and then
steadily declining through early 2020.
The article is available online at this link:
https://academic.oup.com/ntr/article/22/Supplement_1/S96/6035090
|
|
Email to a Friend